Read the full article here.
This content was originally published by the new yorker business. Original publishers retain all rights. It appears here for a limited time before automated archiving. By the new yorker business
Jerome Groopman writes about the National Emerging Infectious Diseases Laboratories, in Boston, which is taking a cautious and deliberate approach to the study of the coronavirus and possible treatments.